Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Sponsor
Sponsor
For Practicing Oncologists
Cancer Science: T-cell/tumor-cell tethering antibody shows promise against refractory non-Hodgkin's lymphoma
Sara Hartley, MDLinx Oncology
Today's Oncology News: The HERS+ to HER2- Switch--Clinically Significant?
D Scott Cunningham MD, PhD, MDLinx Oncology
Noninvasive Biochemical Probe Uses Light to Detect Skin Cancers
Dorothy J. Schirf, MD, MDLinx Oncology
  See all
Liver cancer Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer
Hepatology, 06/11/08
Print     Email This Article     Save in My Library   Free Abstract
Hu G et al. - In a study to determine the single and joint associations of coffee consumption and serum gamma-glutamyltransferase (GGT) with the risk of primary liver cancer, it was shown that coffee drinking has an inverse and graded association with the risk of liver cancer. High serum GGT is associated with an increased risk of liver cancer

Methods
  • Study cohorts included 60,323 Finnish participants who were 25-74 years of age and free of any cancer at baseline

Results
  • During a median follow-up period of 19.3 years, 128 participants were diagnosed with an incident liver cancer
  • Multivariable-adjusted hazards ratios of liver cancer in participants who drank 0-1, 2-3, 4-5, 6-7, and 8 cups of coffee daily were 1.00, 0.66, 0.44, 0.38, and 0.32, respectively
  • Further adjustment for serum GGT in subgroup analysis affected the results only slightly
  • Multivariable-adjusted and coffee-adjusted hazard ratio of liver cancer for the highest vs the lowest quartile of serum GGT was 3.13
  • Multivariable-adjusted inverse association between coffee consumption and liver cancer risk persisted when stratified by baseline factors: age more/less than 50 years, current smoker/never smoked/ever smoked, alcohol drinker/never drinker, obese/nonobese, and the highest/lowest three quartiles of serum GGT
  • A combination of very low coffee consumption and high level of serum GGT was associated with nearly 9-fold increased risk

Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.